Cardiac transplantation for end-stage heart disease

M. Argenziano, Daniel J. Goldstein, M. C. Oz, E. A. Rose

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In the nearly 30 years since the first successful human heart transplant, a variety of developments have allowed-this form of cardiac replacement therapy to flourish. These have included improvements in surgical and critical care technology, as well as breakthroughs in immunosuppressive pharmacology, the most notable of which was the introduction of cyclosporine in 1980. Subsequently, indications and exclusion criteria for heart transplantation have evolved, guided by the constraints of a limited donor supply and facilitated by an improved understanding of prognostic risk factors. Current 1- and 5-year survival estimates are encouraging, and despite the frequency of acute rejection, current management strategies have, for the most part, limited the fatal consequences of this complication. Graft atherosclerosis, however, has continued to complicate the posttransplant course of many patients, and despite therapeutic strategies aimed at a variety of potential pathogenic mechanisms, this entity remains the most common cause of late death after transplantation. In these patients and other victims of allograft failure, retransplantation remains a viable option. Finally, the recent trend of selecting increasingly critically ill transplant recipients, although not associated with inferior or survival, has driven the costs of this form of cardiac replacement therapy to unprecedented levels. These issues, as well as current developments in the fields of mechanical cardiac assistance, xenotransplantation, and cardiac gene therapy, will certainly result in a continually evolving role for cardiac transplantation in the treatment of end-stage heart disease.

Original languageEnglish (US)
Pages (from-to)349-355
Number of pages7
JournalCardiology in Review
Volume7
Issue number6
StatePublished - 1999
Externally publishedYes

Fingerprint

Heart Transplantation
Heart Diseases
Transplants
Heterologous Transplantation
Survival
Therapeutics
Critical Care
Immunosuppressive Agents
Critical Illness
Genetic Therapy
Cyclosporine
Allografts
Cause of Death
Atherosclerosis
Transplantation
Tissue Donors
Pharmacology
Technology
Costs and Cost Analysis

Keywords

  • Allograft rejection
  • Cardiac transplantation
  • End-stage heart failure
  • Immunosuppression

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Argenziano, M., Goldstein, D. J., Oz, M. C., & Rose, E. A. (1999). Cardiac transplantation for end-stage heart disease. Cardiology in Review, 7(6), 349-355.

Cardiac transplantation for end-stage heart disease. / Argenziano, M.; Goldstein, Daniel J.; Oz, M. C.; Rose, E. A.

In: Cardiology in Review, Vol. 7, No. 6, 1999, p. 349-355.

Research output: Contribution to journalArticle

Argenziano, M, Goldstein, DJ, Oz, MC & Rose, EA 1999, 'Cardiac transplantation for end-stage heart disease', Cardiology in Review, vol. 7, no. 6, pp. 349-355.
Argenziano, M. ; Goldstein, Daniel J. ; Oz, M. C. ; Rose, E. A. / Cardiac transplantation for end-stage heart disease. In: Cardiology in Review. 1999 ; Vol. 7, No. 6. pp. 349-355.
@article{3f32dd68b7e0444e82123064e0d1f8ad,
title = "Cardiac transplantation for end-stage heart disease",
abstract = "In the nearly 30 years since the first successful human heart transplant, a variety of developments have allowed-this form of cardiac replacement therapy to flourish. These have included improvements in surgical and critical care technology, as well as breakthroughs in immunosuppressive pharmacology, the most notable of which was the introduction of cyclosporine in 1980. Subsequently, indications and exclusion criteria for heart transplantation have evolved, guided by the constraints of a limited donor supply and facilitated by an improved understanding of prognostic risk factors. Current 1- and 5-year survival estimates are encouraging, and despite the frequency of acute rejection, current management strategies have, for the most part, limited the fatal consequences of this complication. Graft atherosclerosis, however, has continued to complicate the posttransplant course of many patients, and despite therapeutic strategies aimed at a variety of potential pathogenic mechanisms, this entity remains the most common cause of late death after transplantation. In these patients and other victims of allograft failure, retransplantation remains a viable option. Finally, the recent trend of selecting increasingly critically ill transplant recipients, although not associated with inferior or survival, has driven the costs of this form of cardiac replacement therapy to unprecedented levels. These issues, as well as current developments in the fields of mechanical cardiac assistance, xenotransplantation, and cardiac gene therapy, will certainly result in a continually evolving role for cardiac transplantation in the treatment of end-stage heart disease.",
keywords = "Allograft rejection, Cardiac transplantation, End-stage heart failure, Immunosuppression",
author = "M. Argenziano and Goldstein, {Daniel J.} and Oz, {M. C.} and Rose, {E. A.}",
year = "1999",
language = "English (US)",
volume = "7",
pages = "349--355",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Cardiac transplantation for end-stage heart disease

AU - Argenziano, M.

AU - Goldstein, Daniel J.

AU - Oz, M. C.

AU - Rose, E. A.

PY - 1999

Y1 - 1999

N2 - In the nearly 30 years since the first successful human heart transplant, a variety of developments have allowed-this form of cardiac replacement therapy to flourish. These have included improvements in surgical and critical care technology, as well as breakthroughs in immunosuppressive pharmacology, the most notable of which was the introduction of cyclosporine in 1980. Subsequently, indications and exclusion criteria for heart transplantation have evolved, guided by the constraints of a limited donor supply and facilitated by an improved understanding of prognostic risk factors. Current 1- and 5-year survival estimates are encouraging, and despite the frequency of acute rejection, current management strategies have, for the most part, limited the fatal consequences of this complication. Graft atherosclerosis, however, has continued to complicate the posttransplant course of many patients, and despite therapeutic strategies aimed at a variety of potential pathogenic mechanisms, this entity remains the most common cause of late death after transplantation. In these patients and other victims of allograft failure, retransplantation remains a viable option. Finally, the recent trend of selecting increasingly critically ill transplant recipients, although not associated with inferior or survival, has driven the costs of this form of cardiac replacement therapy to unprecedented levels. These issues, as well as current developments in the fields of mechanical cardiac assistance, xenotransplantation, and cardiac gene therapy, will certainly result in a continually evolving role for cardiac transplantation in the treatment of end-stage heart disease.

AB - In the nearly 30 years since the first successful human heart transplant, a variety of developments have allowed-this form of cardiac replacement therapy to flourish. These have included improvements in surgical and critical care technology, as well as breakthroughs in immunosuppressive pharmacology, the most notable of which was the introduction of cyclosporine in 1980. Subsequently, indications and exclusion criteria for heart transplantation have evolved, guided by the constraints of a limited donor supply and facilitated by an improved understanding of prognostic risk factors. Current 1- and 5-year survival estimates are encouraging, and despite the frequency of acute rejection, current management strategies have, for the most part, limited the fatal consequences of this complication. Graft atherosclerosis, however, has continued to complicate the posttransplant course of many patients, and despite therapeutic strategies aimed at a variety of potential pathogenic mechanisms, this entity remains the most common cause of late death after transplantation. In these patients and other victims of allograft failure, retransplantation remains a viable option. Finally, the recent trend of selecting increasingly critically ill transplant recipients, although not associated with inferior or survival, has driven the costs of this form of cardiac replacement therapy to unprecedented levels. These issues, as well as current developments in the fields of mechanical cardiac assistance, xenotransplantation, and cardiac gene therapy, will certainly result in a continually evolving role for cardiac transplantation in the treatment of end-stage heart disease.

KW - Allograft rejection

KW - Cardiac transplantation

KW - End-stage heart failure

KW - Immunosuppression

UR - http://www.scopus.com/inward/record.url?scp=0032722819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032722819&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 349

EP - 355

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 6

ER -